D-0573-2022 Class II Ongoing

Recalled by RISING PHARMACEUTICALS — East Brunswick, NJ

FDA drug recall D-0573-2022 was initiated by RISING PHARMACEUTICALS on Feb 7, 2022 and is designated Class II. Reason for recall: Failed Tablet Specifications: Recall of this drug product was voluntarily initiated by the manufacturer due to a market complaint, which stated that a tablet in the sealed bottle was twice larger in… The recall status is ongoing. Affected quantity: 2220 100-count bottles.

Recall details

Product Type
Drugs
Report Date
Mar 2, 2022
Initiation Date
Feb 7, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2220 100-count bottles

Product description

Methylphenidate Hydrochloride Chewable Tablets, 2.5 mg, 100-count bottle, Rx Only, Manufactured for: Rising Pharmaceuticals Inc., Saddle Brook, NJ 07863, NDC 64980-221-01

Reason for recall

Failed Tablet Specifications: Recall of this drug product was voluntarily initiated by the manufacturer due to a market complaint, which stated that a tablet in the sealed bottle was twice larger in size when compared to the remaining tablets. This complaint is second of its kind.

Distribution pattern

Nationwide in the USA

Code information

lot# 25910009, Exp 01/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0573-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0573-2022. Report a data issue: hello@regdatalab.com.